m6A target microRNAs in serum for cancer detection

Molecular Cancer

Weiqing Shao¹  Zhifei Lin¹  Yitong Li¹  Chenhe Yi¹  Jing Lin¹  Bo Zhang¹  Jinhong Chen¹  Zhenmei Chen¹  Baorui Tao¹ 

[1] Department of General Surgery, Huashan Hospital, Fudan University, 12 Middle Wulumuqi Road, 200040, Shanghai, PR China;Cancer Metastasis Institute, Fudan University, 200040, Shanghai, PR China;

关键词: Liquid biopsy;    mA;    microRNA;    Diagnosis;    Pan-cancer;   

DOI  :  10.1186/s12943-021-01477-6

来源: Springer

【 摘 要 】

Recent studies have revealed the significant dysregulation of m6A level in peripheral blood in several cancer types and its value in diagnosis. Nonetheless, a biomarker for accurate screening of multiple cancer types has not been established based on the perspective of m6A modification. In this study, we aimed to develop a serum diagnostic signature based on the m6A target miRNAs for the mass detection of cancer. A total of 14965 serum samples with 12 cancer types were included. Based on training cohort (n=7299), we developed the m6A-miRNAs signature using a support vector machine algorithm for cancer detection. The m6A-miRNAs signature showed high accuracy, and its area under the curve (AUC) in the training, internal validation and external validation cohort reached 0.979 (95%CI 0.976 - 0.982), 0.976 (95%CI 0.973 - 0.979) and 0.936 (95%CI 0.922 - 0.951), respectively. In the performance of distinguishing cancer types, the m6A-miRNAs signature showed superior sensitivity in each cancer type and presented a satisfactory AUC in identifying lung cancer, gastric cancer and hepatocellular carcinoma. Additionally, the diagnostic performance of m6A-miRNAs was not interfered by the gender, age and benign disease. In short, this study revealed the value of serum circulating m6A miRNAs in cancer detection and provided a new direction and strategy for the development of novel biomarkers with high accuracy, low cost and less invasiveness for mass cancer screening, such as RNA modification.

【 授权许可】

CC BY